Best of ASCO - 2014 Annual Meeting

 

Welcome

Attend this session at the
2019 ASCO Annual Meeting!


Session: Gynecologic Cancer

Type: Poster Session

Time: Saturday June 1, 1:15 PM to 4:15 PM

Location: Hall A

Recurrence of ovarian cancer in BRCAwt patients without maintenance therapy: Real-world evidence.

Sub-category:
Ovarian Cancer

Category:
Gynecologic Cancer

Meeting:
2019 ASCO Annual Meeting

Abstract No:
5547

Poster Board Number:
Poster Session (Board #370)

Citation:
J Clin Oncol 37, 2019 (suppl; abstr 5547)

Author(s): Melinda Louie-Gao, Ebru Aydin, Premal H. Thaker; TESARO, Inc., Waltham, MA; Washington University School of Medicine, St. Louis, MO

Abstract Disclosures

Abstract:

Background: Development of platinum resistance is a major clinical challenge in ovarian cancer (OC) treatment. In the phase 3 ENGOT-OV16/NOVA trial of the poly(ADP-ribose) polymerase inhibitor (PARPi) niraparib, 55% of BRCA wild-type (BRCAwt) patients (pts) receiving placebo developed platinum resistance after their last platinum-based therapy (ie, progressive disease within 6 months of their last chemotherapy [CT] dose). Niraparib, a PARPi approved for the maintenance treatment of adult pts with recurrent OC following platinum-based CT, significantly prolongs progression-free survival (PFS). This real-world data analysis investigated the risk of platinum eligibility loss for BRCAwt pts who did not receive maintenance therapy after platinum treatment. Methods: This retrospective study identified 5,535 pts with OC from January 2011–October 2018 using data from Flatiron, a longitudinal, demographically and geographically diverse database derived from records of > 265 cancer clinics and > 2 million US cancer pts. BRCAwt pts who had received ≥2 lines of platinum-based CT, had disease progression ≥6 months after their previous line of therapy, and had no maintenance therapy (PARPi, bevacizumab, or CT agents) after their current treatment were included. Kaplan-Meier analysis was used to estimate the probability of pts initiating next treatment or death, whichever occurred first, within 6 months. Results: Of 5,535 pts diagnosed with OC, 147 BRCAwt pts met the inclusion/exclusion criteria of this analysis (similar to ENGOT-OV16/NOVA placebo arm). An estimated 56% of pts received the next treatment or died within 6 months after their last platinum-based therapy. Median time to next therapy or death was 5.1 months (95% confidence interval, 3.1–7.2). Conclusions: Our real-world data analysis shows that 56% of BRCAwt pts who received platinum-based treatment without maintenance therapy had recurrent OC within 6 months, classifying them as platinum resistant. Use of maintenance treatment options, such as niraparib, has been shown to significantly prolong PFS after platinum-based CT and may be beneficial in extending the platinum-free interval, enabling pts to remain eligible for further platinum therapy.

 
Other Abstracts in this Sub-Category:

 

1. Combination of niraparib and bevacizumab versus niraparib alone as treatment of recurrent platinum-sensitive ovarian cancer: A randomized controlled chemotherapy-free study—NSGO-AVANOVA2/ENGOT-OV24.

Meeting: 2019 ASCO Annual Meeting Abstract No: 5505 First Author: Mansoor Raza Mirza
Category: Gynecologic Cancer - Ovarian Cancer

 

2. Olaparib monotherapy versus (vs) chemotherapy for germline BRCA-mutated (gBRCAm) platinum-sensitive relapsed ovarian cancer (PSR OC) patients (pts): Phase III SOLO3 trial.

Meeting: 2019 ASCO Annual Meeting Abstract No: 5506 First Author: Richard T. Penson
Category: Gynecologic Cancer - Ovarian Cancer

 

3. Randomized phase II CLIO study on olaparib monotherapy versus chemotherapy in platinum-resistant ovarian cancer.

Meeting: 2019 ASCO Annual Meeting Abstract No: 5507 First Author: Adriaan Vanderstichele
Category: Gynecologic Cancer - Ovarian Cancer

 

More...